Does hyperinsulinemia suppress hepatic SHBG to raise free testosterone and drive androgen activity in women with PCOS?

The relationship between insulin and androgen activity is a central component of women's metabolic and reproductive health, particularly in the context of Polycystic Ovary Syndrome (PCOS). Research consistently demonstrates that hyperinsulinemia plays a causal role in increasing androgen bioavailability by suppressing the liver's production of sex hormone-binding globulin (SHBG).

Mechanistic evidence

Hyperinsulinemia exerts a direct inhibitory effect on hepatic SHBG production through complex transcriptional signaling.

• Transcriptional Regulation: Insulin suppresses the expression of hepatocyte nuclear factor 4 alpha (HNF-4α), which is the primary transcription factor required for SHBG gene expression.
• Molecular Pathways: The suppression involves the activation of sterol regulatory element-binding proteins (SREBPs) and the induction of hepatic lipogenesis. These processes further repress the SHBG promoter, significantly reducing the synthesis of the protein within hepatocytes.
• SHBG Function: As the liver is the primary source of circulating SHBG, this transcriptional downregulation leads to a marked decrease in serum levels. SHBG serves as the principal carrier for testosterone; by binding it with high affinity, it renders the hormone biologically inactive.

Clinical evidence and PCOS

In clinical practice, the inverse relationship between insulin and SHBG is a hallmark of hyperandrogenic states.

• Androgen Bioavailability: When SHBG levels drop due to hyperinsulinemia, the equilibrium shifts toward the "free hormone" state. This increases the concentration of free testosterone—the fraction capable of entering target cells to exert biological effects.
• The PCOS Connection: In women with PCOS, compensatory hyperinsulinemia (resulting from insulin resistance) is a primary driver of low SHBG. This mechanism is frequently assessed using the Free Androgen Index (FAI), where low SHBG levels serve as the denominator, highlighting how its reduction directly inflates systemic androgen activity.
• Intervention Data: Clinical trials have shown that interventions aimed at lowering insulin levels, such as myo-inositol supplementation or lifestyle changes, successfully increase SHBG concentrations and subsequently reduce clinical symptoms of hyperandrogenism, such as hirsutism and acne.

Bottom line

Hyperinsulinemia suppresses hepatic SHBG production by downregulating HNF-4α, which increases the bioavailability of free testosterone. This mechanism is a scientifically established driver of the hyperandrogenic symptoms observed in PCOS.